Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Counterfeit Screening Tool Gets Field Test In Ghana; Corning Prepares Device For Mass Production

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA currently employs the CD3 in its laboratories and at a number of international mail facilities and other points of entry to the U.S. to screen cosmetics, foods, medical devices and cigarettes, as well as drugs.

You may also be interested in...



FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.

FDA’s New Criminal Investigations Chief Wants Global Reach

Recently appointed Office of Criminal Investigations Director George Karavetsos talks about expanding the global presence of his office to protect product safety in the U.S. in an interview.

FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS075580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel